Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI1815368
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Ophthalmic, Intravitreal
01
Overview
BI1815368 is an investigational bispecific Nanobody developed by Boehringer Ingelheim for the treatment of retinal vascular disorders, including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The molecule is designed to simultaneously bind and neutralize two pro-angiogenic and pro-inflammatory factors: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). Dual inhibition of these pathways is intended to stabilize the retinal vasculature more effectively than anti-VEGF monotherapy, potentially leading to improved visual outcomes and reduced treatment frequency. BI1815368 is administered via intravitreal injection and is currently undergoing Phase 2 clinical evaluation.
- Other names
- VEGF/Ang-2 bispecific Nanobody
02
Targets
ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on BI1815368.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI1815368.